Portolan Capital Management’s CorMedix CRMD Stock Holding History

Portolan Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-283,663	Closed	-$3.49M	–	125
2025 Q2	$3.49M	Buy	+283,663	New	+$3.13M	0.22%	101

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Portolan Capital Management's CRMD Position: Q3 2025 in Review

Portolan Capital Management sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 283,663 shares — an estimated $3.49M sold.

Portolan Capital Management first reported a position in CRMD in Q2 2025 and held it in 1 quarter. The position peaked at $3.49M in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

Portolan Capital Management reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
Portolan Capital Management sold 283,663 CorMedix shares in Q3 2025, an estimated $3.49M.
Portolan Capital Management first reported a position in CorMedix in Q2 2025 and held it in 1 quarter.
Portolan Capital Management's CorMedix position peaked at $3.49M in Q2 2025.
190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on Portolan Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.